BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Intellegens

Intellegens logo

Founded
2017
Publications
5

Technologies

AI Companies (Drug Discovery)

Intellegens is a spin-out from the University of Cambridge that has developed a unique Artificial Intelligence (AI) method for training neural networks from incomplete data sets. The technique, developed in the Department of Physics, is being applied to drug discovery and material design problems.

We have developed a unique capability to train and predict models from incomplete data. The technology can be used to link large, easy to acquire, databases with small, hard to acquire datasets. Generated models can be used to design, predict and identify errors.

Given a fragmented dataset the algorithm can learn the underlying correlations to estimate the missing knowledge of how candidate drugs act on proteins and therefore help clients to design new drug cocktails to activate the right proteins to cure disease

Become a Member to view additional information about this company